This is a working overview of regulatory status, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-24 and is reviewed periodically as new material appears.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
They also included giving the Reserve Forces and Cadets Associations the power to produce an annual report to Parliament on the state of the volunteer reserves (the Royal Naval Reserve, The Royal Marines Reserve, the Army Reserve and the Royal Auxiliary Air Force). In January 2021, the Army Reserve trained strength stood at 26,820. (This figure excludes recruits undergoing phase 1 training and various non-deployable categories such as University Officers' Training Corps). During 2020, three reserve infantry battalions, 7 Rifles and 5 Fusiliers followed by 6 Rifles, provided the framework battalion for peacekeeping in Cyprus and over the winter 20/21 the Royal Yeomanry provided a composite squadron for a six-month tour on armoured reconnaissance as part of Britain's forward presence in Estonia. Army Reservists have a minimum commitment to serve 27 training days per year or 19 days for some national units. This period normally includes a two-week period of continuous training either as an Army Reserve unit, on courses or attached to a Regular unit. Army Reserve soldiers are paid at a similar rate to their regular equivalents while engaged on military activities.
Sir Frederick Gowland Hopkins (20 June 1861 – 16 May 1947) was an English biochemist who was awarded the Nobel Prize in Physiology or Medicine in 1929, with Christiaan Eijkman, for the discovery of vitamins. He also discovered the amino acid tryptophan, in 1901. He was President of the Royal Society from 1930 to 1935.
== Substrate specificity == Serine proteases are characterised by a distinctive structure, consisting of two beta-barrel domains that converge at the catalytic active site. These enzymes can be further categorised based on their substrate specificity as either trypsin-like, chymotrypsin-like or elastase-like.
Sources: en.wikipedia.org
===== MeSH D08.811.682.660 – oxidoreductases acting on ch-ch group donors ===== MeSH D08.811.682.660.150 – acyl-coa dehydrogenases MeSH D08.811.682.660.150.100 – acyl-coa dehydrogenase MeSH D08.811.682.660.150.150 – acyl-coa dehydrogenase, long-chain MeSH D08.811.682.660.150.200 – acyl-CoA oxidase MeSH D08.811.682.660.150.300 – butyryl-coa dehydrogenase MeSH D08.811.682.660.200 – cholestenone 5alpha-reductase MeSH D08.811.682.660.250 – coproporphyrinogen oxidase MeSH D08.811.682.660.275 – dihydrodipicolinate reductase MeSH D08.811.682.660.300 – dihydroorotate oxidase MeSH D08.811.682.660.325 – dihydrouracil dehydrogenase (nad+) MeSH D08.811.682.660.350 – dihydrouracil dehydrogenase (nadp) MeSH D08.811.682.660.385 – electron transport complex ii MeSH D08.811.682.660.385.500 – succinate dehydrogenase MeSH D08.811.682.660.387 – enoyl-(acyl-carrier-protein) reductase (nadh) MeSH D08.811.682.660.390 – enoyl-(acyl-carrier protein) reductase (nadph, b-specific) MeSH D08.811.682.660.425 – Glutaryl-CoA dehydrogenase MeSH D08.811.682.660.462 – isovaleryl-coa dehydrogenase MeSH D08.811.682.660.490 – 15-oxoprostaglandin 13-reductase MeSH D08.811.682.660.500 – prephenate dehydrogenase MeSH D08.811.682.660.600 – protoporphyrinogen oxidase MeSH D08.811.682.660.750 – succinate dehydrogenase MeSH D08.811.682.660.900 – testosterone 5-alpha-Reductase
== Research areas == RCB engages in contemporary research at the interface of disciplines constituting biotechnology in its broadest definition. Research programmes aim to integrate science, engineering, medicine and agriculture in biotechnology and emphasize on their relevance to the regional societies. A broad range of research areas planned include:
=== First allegation of domestic abuse === In October 2020, Zverev's ex-girlfriend Olga Sharypova, in an article in Racquet magazine by journalist Ben Rothenberg, accused Zverev of physically and emotionally abusing her over the course of their relationship. Sharypova named multiple instances where Zverev allegedly became violent towards her, including punching her in the face during an argument that took place in the pair's hotel room while Zverev was competing at the 2019 Laver Cup. Zverev denied the allegations and issued a statement after Sharypova's initial accusations: "I very much regret that she makes such statements. Because the accusations are simply not true." A second article by Rothenberg about the allegations was released in August 2021, this time in Slate magazine. The second article picked up Sharypova's story where the first left off. It includes this description of the alleged violence escalating in October 2019:
=== Sarcomere assembly === In addition to sarcomere activity, it has been shown that myomesin also plays a role in the assembly of the sarcomere. In order for myomesin to be implemented into the sarcomere, myosin and titin must be present, indicating that myomesin is the last component to be added during assembly of the lattice. It is believed that this postponed addition is due to the role of myomesin to act as an "integrity check" to ensure the sarcomere has been formed correctly and monitor its integrity. This is extremely important as if even one piece of the M-line is missing, the A-band of the sarcomere will collapse and the muscle will be paralyzed.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.